Johnson & Johnson $JNJ Shares Purchased by Golden State Equity Partners

Golden State Equity Partners grew its position in shares of Johnson & Johnson (NYSE:JNJ) by 20.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 21,491 shares of the company’s stock after purchasing an additional 3,654 shares during the period. Johnson & Johnson accounts for about 0.7% of Golden State Equity Partners’ investment portfolio, making the stock its 26th largest position. Golden State Equity Partners’ holdings in Johnson & Johnson were worth $3,985,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of JNJ. Vanguard Group Inc. grew its stake in Johnson & Johnson by 1.3% in the 2nd quarter. Vanguard Group Inc. now owns 237,047,859 shares of the company’s stock worth $36,209,060,000 after acquiring an additional 3,085,180 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Johnson & Johnson by 2.1% during the second quarter. Geode Capital Management LLC now owns 60,609,476 shares of the company’s stock worth $9,227,988,000 after purchasing an additional 1,225,676 shares during the last quarter. Norges Bank purchased a new stake in shares of Johnson & Johnson in the second quarter valued at $4,877,174,000. Bank of New York Mellon Corp increased its stake in Johnson & Johnson by 2.7% in the second quarter. Bank of New York Mellon Corp now owns 23,802,503 shares of the company’s stock valued at $3,635,832,000 after purchasing an additional 620,039 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its position in Johnson & Johnson by 0.3% during the second quarter. Charles Schwab Investment Management Inc. now owns 18,951,337 shares of the company’s stock worth $2,894,979,000 after buying an additional 52,074 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have commented on the company. Citigroup lifted their price target on Johnson & Johnson from $215.00 to $232.00 and gave the company a “buy” rating in a report on Thursday, December 11th. Stifel Nicolaus boosted their target price on shares of Johnson & Johnson from $165.00 to $190.00 and gave the company a “hold” rating in a report on Wednesday, October 15th. Royal Bank Of Canada set a $240.00 price target on shares of Johnson & Johnson in a report on Wednesday, December 17th. UBS Group upped their price objective on Johnson & Johnson from $190.00 to $214.00 and gave the stock a “buy” rating in a report on Tuesday, October 14th. Finally, Johnson Rice set a $190.00 target price on Johnson & Johnson and gave the stock a “hold” rating in a research report on Wednesday, October 22nd. Four research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $211.25.

Johnson & Johnson Price Performance

Johnson & Johnson stock opened at $207.26 on Monday. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50. The firm has a market capitalization of $499.35 billion, a P/E ratio of 20.01, a PEG ratio of 2.13 and a beta of 0.34. The firm has a fifty day moving average of $201.17 and a 200-day moving average of $183.07. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $215.18.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. The firm had revenue of $24.02 billion during the quarter. As a group, analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Tuesday, February 24th will be issued a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 2.5%. The ex-dividend date is Tuesday, February 24th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 50.19%.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.